Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The company's topical semi-solid and liquid products are used in various applications that range from cosmetics and cosmeceuticals; and the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. It sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was incorporated in 1977 and is based in Buena, New Jersey.
IPO Year: n/a
Exchange: NASDAQ
Website: teligent.com
25-NSE - Teligent, Inc. (0000352998) (Subject)
8-K - Teligent, Inc. (0000352998) (Filer)
8-K - Teligent, Inc. (0000352998) (Filer)
8-K - Teligent, Inc. (0000352998) (Filer)
10-Q - Teligent, Inc. (0000352998) (Filer)
8-K - Teligent, Inc. (0000352998) (Filer)
DEFA14A - Teligent, Inc. (0000352998) (Filer)
DEFA14A - Teligent, Inc. (0000352998) (Filer)
10-Q - Teligent, Inc. (0000352998) (Filer)
DEF 14A - Teligent, Inc. (0000352998) (Filer)
Fastest customizable press release news feed in the world
BUENA, N.J., Oct. 14, 2021 /PRNewswire/ -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company ("Teligent" or the "Company"), today announced that the Company has, together with certain of its affiliates, filed for voluntary protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware to pursue a sale process that is intended to maximize the value of the Company. The Company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several interested parties. The Company expects to consummate a sale of the entire busi
–Update on FDA Inspection of Buena Facility–Assessing New Growth Opportunities in Injectables–Conference Call to Be Held on August 16, 2021 at 8:30 am Eastern Standard Time –Dial in: (877) 407-0792 US Toll Free Number (201) 689-8263 International Number Confirmation Number: 13721972 BUENA, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the second quarter of 2021 and provided a business update. "Product demand in our core business was impacted by a combination of factors, including remediation-related activities, the ongoing effects of the COVID-19 pandemic, and modest ge
BUENA, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Monday, August 16th, 2021 to discuss the second quarter ended June 30, 2021 financial results and business update. Conference Call InformationDate: Monday, August 16, 2021Time: 8:30 a.m. Eastern TimeDial-in numbers: Toll Free: 877-407-0792 International: 201-689-8263Conference ID: 13721972 This call is available via webcast and can be accessed under News & Events in the Investor Relations section of Teligent, Inc.'s website at www.teligent.com. About Teligent, Inc.T
Scheduled to Reconvene on July 21, 2021Company Urgently Encourages Stockholders to Vote BUENA, N.J., June 30, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company (the "Company"), announced today that its Annual Meeting of Stockholders, scheduled for June 18, 2021 and adjourned to June 30, 2021, was convened and adjourned without any business being conducted due to the fact that there were not sufficient votes to approve all of the proposals presented at the Annual Meeting. The Company is adjourning the meeting in order to solicit additional votes to meet the requirements for approval of the proposals presented. The Annual Mee
Scheduled to Reconvene on June 30, 2021Company Urgently Encourages Stockholders to Vote BUENA, N.J., June 18, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company (the "Company"), announced today that its Annual Meeting of Stockholders, scheduled for June 18, 2021, was convened and adjourned without any business being conducted due to the fact that there were not sufficient votes to approve all of the proposals presented at the Annual Meeting. The Company is adjourning the meeting in order to solicit additional votes to meet the requirements for approval of the proposals presented. The Special Meeting will be reconvened at 10:
–Continued Remediation Progress Being Made–Reiterating Prior Guidance of Informing FDA on Inspection Readiness During 3Q2021–Conference Call to Be Held on May 25, 2021 at 4:30 pm Eastern Standard Time –Dial in: (800) 708-4540 US Toll Free Number (847) 619-6397 US Number Confirmation Number: 50161966 BUENA, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the first quarter of 2021 and provided a business update. "As we prepare for the second half of 2021, we are pleased with the progress being made with respect to remediation, our strengthened capital position, and the recent
NEW YORK, NY / ACCESSWIRE / May 25, 2021 / Teligent, Inc. (NASDAQ:TLGT) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 25, 2021 at 8:30 AM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/event/presentation/79643To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile.About Investor NetworkInvestor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professiona
BUENA, N.J., May 21, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Tuesday, May 25th, 2021 to discuss the first quarter ended March 31, 2021 financial results and business update. Conference Call InformationDate: Tuesday, May 25, 2021Time: 8:30 a.m. Eastern TimeDial-in numbers: Toll Free: (866) 393-8366 International: 409-350-3154Conference ID: 4758457 This call is available via webcast and can be accessed under News & Events in the Investor Relations section of Teligent, Inc.'s website at www.teligent.com. About Teligent, Inc.Telig
– Significantly strengthened balance sheet and cash position – Continued FDA Warning Letter remediation efforts – Anticipate informing FDA on inspection readiness during 3Q2021 – Conference Call to be held on May 4, 2021 at 4:30 pm Eastern Standard Time – Dial in: (800) 708-4540 US Toll Free Number (847) 619-6397 US Number Confirmation Number: 50161966 BUENA, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2020. "We are pleased with the progress our team has made at Teligent. Despite the COVID-19 pandemic presenting unfore
BUENA, N.J., April 15, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT) ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced the hiring and appointment of Ernest R. De Paolantonio as Chief Financial Officer of the Company, effective April 15, 2021. Timothy B. Sawyer, President and CEO of the Company, commented, "We are very pleased that Ernie has agreed to join our Teligent team. Over the last several months, we have made key additions to our leadership team, and the appointment of Ernie to the CFO position reflects our commitment to bring in highly talented and experienced individuals who have a strong track record of success. E
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Teligent, Inc. (0000352998) (Issuer)
3 - Teligent, Inc. (0000352998) (Issuer)
4 - Teligent, Inc. (0000352998) (Issuer)
4 - Teligent, Inc. (0000352998) (Issuer)
4 - Teligent, Inc. (0000352998) (Issuer)
4 - Teligent, Inc. (0000352998) (Issuer)
4 - Teligent, Inc. (0000352998) (Issuer)
4/A - Teligent, Inc. (0000352998) (Issuer)
4 - Teligent, Inc. (0000352998) (Issuer)
4 - Teligent, Inc. (0000352998) (Issuer)
Live Leadership Updates
BUENA, N.J., April 15, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT) ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced the hiring and appointment of Ernest R. De Paolantonio as Chief Financial Officer of the Company, effective April 15, 2021. Timothy B. Sawyer, President and CEO of the Company, commented, "We are very pleased that Ernie has agreed to join our Teligent team. Over the last several months, we have made key additions to our leadership team, and the appointment of Ernie to the CFO position reflects our commitment to bring in highly talented and experienced individuals who have a strong track record of success. E
BUENA, N.J., Feb. 23, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed Carter Pate to its Board of Directors, effective immediately. Mr. Pate will serve on the Audit and Nominating and Corporate Governance Committees. Mr. Pate leads a family-owned investment firm and serves on the Board of Directors at multiple companies, including Global Step and Advanced Emissions Solutions, Inc. He excels at leading companies through moments of change to drive business objectives and redefine their possibilities for growth. John Celentano, Chairman of Teligent's Board of Dire
BUENA, N.J., Feb. 16, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed industry veteran William S. Marth to its Board of Directors, effective immediately. Mr. Marth brings over 25 years of expertise and a proven track record of leading companies in the generic pharmaceutical and contract manufacturing industries. John Celentano, Chairman of Teligent's Board of Directors, commented on the appointment, stating that "We are excited to have Bill join Teligent's Board of Directors. He is a strategic leader with extensive experience in helping businesses transform and
Live finance-specific insights
–Update on FDA Inspection of Buena Facility–Assessing New Growth Opportunities in Injectables–Conference Call to Be Held on August 16, 2021 at 8:30 am Eastern Standard Time –Dial in: (877) 407-0792 US Toll Free Number (201) 689-8263 International Number Confirmation Number: 13721972 BUENA, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the second quarter of 2021 and provided a business update. "Product demand in our core business was impacted by a combination of factors, including remediation-related activities, the ongoing effects of the COVID-19 pandemic, and modest ge
BUENA, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Monday, August 16th, 2021 to discuss the second quarter ended June 30, 2021 financial results and business update. Conference Call InformationDate: Monday, August 16, 2021Time: 8:30 a.m. Eastern TimeDial-in numbers: Toll Free: 877-407-0792 International: 201-689-8263Conference ID: 13721972 This call is available via webcast and can be accessed under News & Events in the Investor Relations section of Teligent, Inc.'s website at www.teligent.com. About Teligent, Inc.T
–Continued Remediation Progress Being Made–Reiterating Prior Guidance of Informing FDA on Inspection Readiness During 3Q2021–Conference Call to Be Held on May 25, 2021 at 4:30 pm Eastern Standard Time –Dial in: (800) 708-4540 US Toll Free Number (847) 619-6397 US Number Confirmation Number: 50161966 BUENA, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the first quarter of 2021 and provided a business update. "As we prepare for the second half of 2021, we are pleased with the progress being made with respect to remediation, our strengthened capital position, and the recent
– Significantly strengthened balance sheet and cash position – Continued FDA Warning Letter remediation efforts – Anticipate informing FDA on inspection readiness during 3Q2021 – Conference Call to be held on May 4, 2021 at 4:30 pm Eastern Standard Time – Dial in: (800) 708-4540 US Toll Free Number (847) 619-6397 US Number Confirmation Number: 50161966 BUENA, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2020. "We are pleased with the progress our team has made at Teligent. Despite the COVID-19 pandemic presenting unfore
BUENA, N.J., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2020. Financial Highlights Third Quarter 2020 vs. Second Quarter 2020 Revenues of $14.3 million, an increase of $0.8 million or 6%, on stronger demand for US topical productsGross profit of $0.1 million, a decrease of $2.4 million driven by additional inventory reserves and write offsProduct development and research expenses of $2.4 million, an increase of $0.5 million due to API write offs for development programs not being
This live feed shows all institutional transactions in real time.
SC 13G/A - Teligent, Inc. (0000352998) (Subject)
SC 13G/A - Teligent, Inc. (0000352998) (Subject)
SC 13G/A - Teligent, Inc. (0000352998) (Subject)